Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant

Shinde, Vivek, Bhikha, Sutika, Hoosain, Zaheer, Archary, Moherndran, Bhorat, Qasim, Fairlie, Lee, Lalloo, Umesh, Masilela, Mduduzi S.L. +41 more·2021·New England Journal of Medicine
DOI 10.1056/nejmoa2103055

Cited by (629)

Items 301–400 of 629

  1. Novavax NVX-COV2373 triggers potent neutralization of Omicron sub-lineages
    Jinal N. Bhiman, Simone I. Richardson, Bronwen E. Lambson, Prudence Kgagudi, Nonkululeko B. Mzindle, Haajira Kaldine, Carol E. Crowther, Glenda Gray, Linda‐Gail Bekker, Vivek Shinde et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  2. Sequencing SARS-CoV-2 from antigen tests
    Ashley Nazario-Toole, Holly M. Nguyen, Hui Xia, Dianne N. Frankel, John W. Kieffer, Thomas F. Gibbons · 2022 · PLoS ONE
  3. Epidemiology and genetic diversity of SARS-CoV-2 lineages circulating in Africa
    Olayinka Sunday Okoh, Nicholas Israel Nii-Trebi, Abdulrokeeb Jakkari, Tosin Titus Olaniran, Tosin Yetunde Senbadejo, Anna Aba Kafintu-kwashie, Emmanuel Oluwatobi Dairo, Tajudeen Oladunni Ganiyu, Ifiokakaninyene Ekpo Akaninyene, Louis Odinakaose Ezediuno et al. · 2022 · iScience
  4. The Potential Roles of BCG Vaccine in the Prevention or Treatment of COVID-19
    Jie Wang, Qian Zhang, Hongmei Wang, Wenping Gong · 2022 · Frontiers in Bioscience-Landmark
  5. Comprehensive narrative review of real-world COVID-19 vaccines: viewpoints and opportunities
    Shelan Liu, Min Kang, Na Zhao, Yali Zhuang, Shijian Li, Tie Song · 2022 · Medical Review
  6. A Nanoparticle-Based COVID-19 Vaccine Candidate Elicits Broad Neutralizing Antibodies and Protects Against SARS-CoV-2 Infection
    Santa-Mariela Olivera-Ugarte, Marilène Bolduc, Marie-Ève Laliberté-Gagné, Léa-Jeanne Blanchette, Caroline Garneau, Maude Fillion, Pierre Savard, Isabelle Dubuc, Louis Flamand, Omar Farnós et al. · 2022 · Nanomedicine Nanotechnology Biology and Medicine
  7. Safety and Efficacy of COVID-19 Vaccine in Africa: Systematic Review
    Selamawit Mengstu, Alemseged Beyene Berha · 2023 · Infection and Drug Resistance
  8. Recent updates on immunological, pharmacological, and alternative approaches to combat COVID-19
    Ammara Saleem, Muhammad Furqan Akhtar, Muhammad Haris, Mohamed M. Abdel‐Daim · 2021 · Inflammopharmacology
  9. COVID-19 Risk Assessment for the Tokyo Olympic Games
    Wenhui Zhu, Jie Feng, Cheng Li, Huimin Wang, Yang Zhong, Lijun Jane Zhou, Xingyu Zhang, Tao Zhang · 2021 · Frontiers in Public Health
  10. A third SARS-CoV-2 spike vaccination improves neutralization of variants-of-concern
    Mitch Brinkkemper, Philip J. M. Brouwer, Pauline Maisonnasse, Marloes Grobben, Tom G. Caniels, Meliawati Poniman, Judith A. Burger, Ilja Bontjer, Melissa Oomen, Joey H. Bouhuijs et al. · 2021 · npj Vaccines
  11. Vaccination as an alternative to non-drug interventions to prevent local resurgence of COVID-19
    Jinhua Pan, Wenlong Zhu, Jie Tian, Zhixi Liu, Ao Xu, Ye Yao, Weibing Wang · 2022 · Infectious Diseases of Poverty
  12. Beyond vaccination: messaging from religious leaders can help increase adherence to COVID-19 mitigation guidelines following vaccination. A research note
    Filip Viskupič, David L. Wiltse, Brittney A. Meyer · 2022 · The Social Science Journal
  13. Recent highlights on Omicron as a new SARS-COVID-19 variant: evolution, genetic mutation, and future perspectives
    Pooja Khairnar, Mukesh Soni, Mayank Handa, Yassine Riadi, Prashant Kesharwani, Rahul Shukla · 2022 · Journal of drug targeting
  14. Immunogenicity, efficacy, and safety of SARS-CoV-2 vaccine dose fractionation: a systematic review and meta-analysis
    Bingyi Yang, Xiaotong Huang, Huizhi Gao, Nancy Leung, Tim K. Tsang, Benjamin John Cowling · 2022 · BMC Medicine
  15. Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein Vaccine
    Gustavo H. Dayan, N. Rouphael, Stephen R. Walsh, Ai-Ying Chen, Nicole Grunenberg, M. Allen, Johannes Antony, K. Asante, A. Bhate, Tatiana H. Beresnev et al. · 2022 · medRxiv
  16. Efficacy and limitations of repurposed drugs and vaccines for COVID-19
    Nensina Murmu, Mrinmoy Sarkar, Sananda Dey, Rahul Manna, Shreya Roy, Tanushree Mondal, Soma Halder, Nandini Bhattacharjee, Sandeep Kumar Dash, Biplab Giri · 2023 · Journal of Medicine Surgery and Public Health
  17. Self-assembled ferritin-based nanoparticles elicit a robust broad-spectrum protective immune response against SARS-CoV-2 variants
    Weiqi Wang, Xianyong Meng, Huan Yong Cui, Cheng Zhang, Shen Wang, Na Feng, Yongkun Zhao, Tiecheng Wang, Feihu Yan, Xianzhu Xia · 2024 · International Journal of Biological Macromolecules
  18. The Immunopathobiology of SARS-CoV-2 Infection
    Milankumar Patel, Farah Shahjin, Jacob D. Cohen, Mahmudul Hasan, Jatin Machhi, Heerak Chugh, Snigdha Singh, Srijanee Das, Tanmay A. Kulkarni, Jonathan Herskovitz et al. · 2021 · FEMS Microbiology Reviews
  19. Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates
    Jewell N. Walters, Blake Schouest, Ami R. Patel, Emma L. Reuschel, Katherine Schultheis, Elizabeth M. Parzych, Igor Maricic, Ebony Nicole Gary, Mansi Purwar, Viviane M. Andrade et al. · 2022 · Vaccine
  20. Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone
    Eveline Santos da Silva, Michel Kohnen, Georges Gilson, Thérèse Staub, Victor Arendt, Christiane Hilger, Jean-Yves Servais, Émilie Charpentier, Olivia Domingues, Chantal J. Snoeck et al. · 2022 · International Journal of Molecular Sciences
  21. Real‐time online monitoring of insect cell proliferation and baculovirus infection using digital differential holographic microscopy and machine learning
    Jort J. Altenburg, Maarten Klaverdijk, Damien Cabosart, Laurent Desmecht, Sonja S. Brunekreeft‐Terlouw, Joshua Both, Vivian I. P. Tegelbeckers, Marieke L. P. M. Willekens, Linda van Oosten, Tessy A. H. Hick et al. · 2022 · Biotechnology Progress
  22. Ability of SpikoGen ®, an Advax‐CpG adjuvanted recombinant spike protein vaccine, to induce cross‐neutralising antibodies against SARS‐CoV ‐2 variants
    Yoshikazu Honda‐Okubo, Anna Antipov, Greiciely O. André, Saghar Barati, Hamidreza Kafi, Nikolai Petrovsky · 2023 · Immunology
  23. Immunogenicity and efficacy of vaccine boosters against SARS-CoV-2 Omicron subvariant BA.5 in male Syrian hamsters
    Rafael Rahal Guaragna Machado, Jordyn L. Walker, Dionna Scharton, Grace H. Rafael, Brooke M. Mitchell, Rachel A. Reyna, William Marciel de Souza, Jianying Liu, David Hughes Walker, Jessica A. Plante et al. · 2023 · Nature Communications
  24. Safety of the NVX-CoV2373 COVID-19 vaccine in randomized placebo-controlled clinical trials
    Katherine Smith, Karim Hegazy, Miranda R. Cai, Irene McKnight, Matthew D. Rousculp, Katia Alves · 2023 · Vaccine
  25. SARS-CoV-2 variants of concern: a review
    Malay S. Sarkar, Irappa Madabhavi · 2022 · Monaldi Archives for Chest Disease
  26. Bioinformatic Analysis of B- and T-cell Epitopes from SARS-CoV-2 Structural Proteins and their Potential Cross-reactivity with Emerging Variants and other Human Coronaviruses
    Diana Laura Pacheco-Olvera, Stephanie Saint Remy-Hernández, María Guadalupe García-Valeriano, Tania Rivera-Hernández, Constantino III Roberto López-Macías · 2022 · Archives of Medical Research
  27. Hybrid Immunity Provides Protective Advantage Over Vaccination or Prior Remote Coronavirus Disease 2019 Alone
    Abinash Virk, Matthew G. Johnson, Daniel L. Roellinger, Christopher G. Scott, Priya Sampathkumar, Laura E. Breeher, Melanie D. Swift · 2023 · Open Forum Infectious Diseases
  28. Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial
    Eimear Kelly, Melanie Greenland, Philip de Whalley, Parvinder K. Aley, Emma L. Plested, Nisha Singh, Stanislava Koleva, Sharon Tonner, Grace C. Macaulay, Robert Charles Read et al. · 2023 · Journal of Infection
  29. An overview of protein-based SARS-CoV-2 vaccines
    Yogesh R. Suryawanshi · 2023 · Vaccine
  30. SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise
    R. Duerr, Keaton M. Crosse, Ana M. Valero-Jimenez, Meike Dittmann · 2021 · Microorganisms
  31. Review: Development of SARS-CoV-2 immuno-enhanced COVID-19 vaccines with nano-platform
    Nawamin Sa-nguanmoo, Katawut Namdee, Mattaka Khongkow, Uracha Ruktanonchai, Yongxiang Zhao, Xing‐Jie Liang · 2021 · Nano Research
  32. A modular protein subunit vaccine candidate produced in yeast confers protection against SARS-CoV-2 in non-human primates
    Neil C. Dalvie, Lisa H. Tostanoski, Sergio A. Rodriguez‐Aponte, Kawaljit Kaur, Sakshi Bajoria, Ozan S. Kumru, Amanda Jezek Martinot, Abishek Chandrashekar, Katherine McMahan, Noe B. Mercado et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  33. Public Sentiment Analysis and Topic Modeling Regarding COVID-19’s Three Waves of Total Lockdown: A Case Study on Movement Control Order in Malaysia
    Abdullah Hussein Alamoodi, Mohammed Rashad Baker, Osamah Shihab Albahri, Bilal Bahaa Zaidan, Aws Alaa Zaidan, Wing‐Kwong Wong, Salem Garfan, Ahmed Shihab Albahri, Miguel Á. Alonso, Ali Najm Jasim et al. · 2022 · KSII Transactions on Internet and Information Systems
  34. Durability of Protection Against COVID-19 Through the Delta Surge for the NVX-CoV2373 Vaccine
    Dean A. Follmann, Allyson Mateja, Michael P. Fay, Craig A. Magaret, Yunda Huang, Youyi Fong, Heather E. Angier, Martha Nason, Cynthia L. Gay, Karen L. Kotloff et al. · 2024 · Clinical Infectious Diseases
  35. Matrix-M adjuvant triggers inflammasome activation and enables antigen cross-presentation through induction of lysosomal membrane permeabilization
    Behdad Zarnegar, Berit Carow, Jens Eriksson, Eva Spennare, Pontus Öhlund, Eray Akpinar, Emelie Bringeland, Ingrid Lekberg Osterman, Lena Lundqvist, Johanna Antti et al. · 2025 · npj Vaccines
  36. The response to COVID 19 across countries and the implications for future pandemics
    Mainul Haque, Marshall Gowere, Nadia Nusrat, Kona Chowdhury, Brian Godman · 2021 · Bangladesh Journal of Medical Science
  37. Potential Immunomodulatory Properties of Biologically Active Components of Spices Against SARS-CoV-2 and Pan β-Coronaviruses
    Sourodip Sengupta, Debina Bhattacharyya, Grishma Kasle, Souvik Karmakar, Omkar Sahu, Anirban Ganguly, Sankar Addya, Jayasri Das Sarma · 2021 · Frontiers in Cellular and Infection Microbiology
  38. Concern About the Adverse Effects of Thrombocytopenia and Thrombosis After Adenovirus-Vectored COVID-19 Vaccination
    MA Haimei · 2021 · Clinical and Applied Thrombosis/Hemostasis
  39. Comparative characterization of antibody responses induced by Ad5-vectored spike proteins of emerging SARS-CoV-2 VOCs
    Busen Wang, Jinghan Xu, Shipo Wu, Zhe Zhang, Zhenghao Zhao, Jun Zhang, Ling Lin Fu, Xiaodong Zai, Yudong Wang, Guanying Zhang et al. · 2022 · Signal Transduction and Targeted Therapy
  40. High-Speed Railways and the Spread of Covid-19
    Jindong Pang, Youle He, Shulin Shen · 2022 · Travel Behaviour and Society
  41. Comparison of Preprint Postings of Randomized Clinical Trials on COVID-19 and Corresponding Published Journal Articles
    Anthony D. Bai, Yunbo Jiang, David L. Nguyen, Carson K. L. Lo, Isabella Z. Stefanova, Kevin Guo, Frank Wang, Cindy Zhang, Kyle Sayeau, Akhil Garg et al. · 2023 · JAMA Network Open
  42. Challenges and Recent Advancements in COVID-19 Vaccines
    Shao-Cheng Wang, Chung-I Rai, Yuan‐Chuan Chen · 2023 · Microorganisms
  43. Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study
    Gustavo H. Dayan, N. Rouphael, Stephen R. Walsh, Ai-Ying Chen, N. Grunenberg, M. Allen, Johannes Antony, A. Bhate, Tatiana H. Beresnev, M. Bonaparte et al. · 2023 · EClinicalMedicine
  44. Comprehensive Understanding and Field Application of COVID-19 Vaccine
    Won Suk Choi · 2021 · Korean Journal of Medicine
  45. Fast and long-lasting immune response to S-trimer COVID-19 vaccine adjuvanted by PIKA
    Yuan Liu, Lianpan Dai, Xiaoli Feng, Ran Gao, Nan Zhang, Bin Wang, Jian-Bao Han, Qing‐Cui Zou, Xiling Guo, Huachen Zhu et al. · 2021 · Molecular Biomedicine
  46. CTN 328: immunogenicity outcomes in people living with HIV in Canada following vaccination for COVID-19 (HIV-COV): protocol for an observational cohort study
    Cecilia Theresa Costiniuk, Joel Singer, Marc‐André Langlois, Iva Kulić, Judy Needham, Ann N. Burchell, Mohammad-Ali Jenabian, Sharon Lynn Walmsley, Mario Ostrowski, Colin M Kovacs et al. · 2021 · BMJ Open
  47. Hacking Commensal Bacteria to Consolidate the Adaptive Mucosal Immune Response in the Gut–Lung Axis: Future Possibilities for SARS-CoV-2 Protection
    Marcela Pereira, Ju Kyoung Oh, Dae‐Kyung Kang, Lars G. Engstrand, Valerie Diane Valeriano · 2022 · BioTech
  48. Effectiveness of 3 COVID-19 Vaccines in Preventing SARS-CoV-2 Infections, January–May 2021, Aragon, Spain
    Alicia del Cura-Bilbao, Héctor López-Mendoza, Armando Chaure-Pardos, Alberto Vergara Ugarriza, Joaquín Guimbao-Bescós · 2022 · Emerging infectious diseases
  49. COH04S1 and beta sequence-modified vaccine protect hamsters from SARS-CoV-2 variants
    Felix Wussow, Mindy Kha, Katelyn Faircloth, Vu H. Nguyen, Angelina Iniguez, Joy Martinez, Yoonsuh Park, Jenny Nguyen, Swagata Kar, Hanné Andersen et al. · 2022 · iScience
  50. The changing health impact of vaccines in the COVID-19 pandemic: A modeling study
    Jamie A. Cohen, Robyn M. Stuart, Jasmina Panovska‐Griffiths, Edinah Mudimu, Romesh Abeysuriya, Cliff C. Kerr, Michael Famulare, Daniel J. Klein · 2023 · Cell Reports
  51. Systematic review and meta-analysis of COVID-19 vaccines safety, tolerability, and efficacy among HIV-infected patients
    Jacques Lukenze Tamuzi, Ley Muyaya Muyaya, Amal Krishna Mitra, Peter Suwirakwenda Nyasulu · 2022 · medRxiv
  52. Nanovaccines: Antigen selection, stabilization, adjuvantation, formulation, and evaluation
    Lisen Lu, Muyang Yang, Deqiang Deng, Xiujuan Shi, Jonathan F. Lovell, Honglin Jin · 2025 · Coordination Chemistry Reviews
  53. Clinical features and laboratory findings first case of B. 1.617.2 (delta) variant concern (VOC) in Iraq
    Rawand Abdulrahman Essa, Sirwan Khalid Ahmed, Dunya Hars Bapir, Chawan P. Abubakr, Shero A. Rasul, Awat Khdir, Zhiar Hussen Wsu · 2021 · Annals of Medicine and Surgery
  54. Durability and expansion of neutralizing antibody breadth following Ad26.COV2.S vaccination of mice
    Shant H. Mahrokhian, Lisa H. Tostanoski, Catherine Jacob-Dolan, Roland C. Zahn, Frank Wegmann, Katherine McMahan, Jingyou Yu, Makda S. Gebre, Esther Apraku Bondzie, Huahua Wan et al. · 2022 · npj Vaccines
  55. Nonhuman primate models for evaluation of SARS-CoV-2 vaccines
    Jessica Anne Neil, Maryanne Griffith, Dale Ian Godfrey, Damian F. J. Purcell, Georgia Deliyannis, David Charles Jackson, Steve Rockman, Kanta Subbarao, Terry M. Nolan · 2022 · Expert Review of Vaccines
  56. Homologous and Heterologous Boosting of the Chadox1-S1-S COVID-19 Vaccine With the SCB-2019 Vaccine Candidate: A Randomized, Controlled, Phase 2 Study
    Sue Ann Costa Clemens, Eveline Pı́polo Milan, Eduardo Sprinz, José Cerbino Neto, Filippo Pacciarini, Ping Li, Huiling Chen, Igor V. Smolenov, Andrew John Pollard, Ralf L. Clemens · 2022 · Open Forum Infectious Diseases
  57. Towards novel nano-based vaccine platforms for SARS-CoV-2 and its variants of concern: Advances, challenges and limitations
    Sally A. Helmy, Rasha M. EL Morsi, Soha M. El-Masry, Soha M. El-Masry · 2022 · Journal of Drug Delivery Science and Technology
  58. A review of COVID vaccines: success against a moving target
    S H Chong, Leah Burn, Mark T. K. Cheng, I S Warr, Julia C. Kenyon · 2022 · British Medical Bulletin
  59. Success of nano-vaccines against COVID-19: a transformation in nanomedicine
    Manoj Kumar Sarangi, Sasmita Kumari Padhi, Gautam Rath, Sitansu Sekhar Nanda, Dong Kee Yi · 2022 · Expert Review of Vaccines
  60. COVID-19 breakthrough infections among people living with and without HIV: A statewide cohort analysis
    Xueying Yang, Jiajia Zhang, Ziang Liu, Shujie Chen, Bankole Olatosi, Gregory A. Poland, Sharon Weissman, Xiaoming Li · 2023 · International Journal of Infectious Diseases
  61. Recurring SARS-CoV-2 variants: an update on post-pandemic, co-infections and immune response
    Ashmit Verma, Anjali Manojkumar, Anupam Dhasmana, Manish Kumar Tripathi, Meena Jaggi, Subhash C. Chauhan, Deepak Singh Chauhan, Murali Mohan Yallapu · 2024 · Nanotheranostics
  62. The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice
    Longbo Hu, Yuhua Xu, Liping Wu, Jin Feng, Lu Zhang, Yongjie Tang, Xiang Zhao, Runming Mai, Liyun Chen, Lingling Mei et al. · 2022 · Viruses
  63. Feasibility and efficacy of mass testing for SARS-CoV-2 in a UK university using swab pooling and PCR
    Ben Warne, Jessica A. Enright, Marina Metaxaki, Stewart Fuller, Richard J. Samworth, Gillian Weale, Jon Holgate, Vijay Samtani, Craig Brierley, Dinesh Aggarwal et al. · 2021 · Research Square
  64. Evaluation of mRNA-1273 against SARS-CoV-2 B.1.351 Infection in Nonhuman Primates
    Kizzmekia S. Corbett, Anne P. Werner, Sarah O’ Connell, Matthew Gagné, Lilin Lai, Juan I. Moliva, Barbara J. Flynn, Angela Choi, Matthew J. Koch, Kathryn E. Foulds et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  65. Immunogenicity and In vivo protection of a variant nanoparticle vaccine that confers broad protection against emerging SARS-CoV-2 variants
    James Logue, Robert M. Johnson, Nita Patel, Bin Zhou, Sonia M. Maciejewski, Haixia Zhou, Alyse D. Portnoff, Jing-Hui Tian, Marisa E. McGrath, Robert E. Haupt et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  66. Self-reported mask-related worrying reduces relative avoidance bias toward unmasked faces in individuals with low Covid19 anxiety syndrome
    Anand Krishna, Johannes Rodrigues, Vanessa Mitschke, Andreas B. Eder · 2021 · Cognitive Research Principles and Implications
  67. Mapping the intersection of nanotechnology and SARS-CoV-2/COVID-19: A bibliometric analysis
    Xuejuan Zhang, Mengqin Guo, Zhengwei Huang, Ying Huang, Chuanbin Wu, Xin Pan · 2022 · Infectious Medicine
  68. Neutralization activity of sera/IgG preparations from fully BNT162b2 vaccinated individuals against SARS-CoV-2 Alpha, Beta, Gamma, Delta, and Kappa variants
    Masayuki Amano, Sachiko Otsu, Kenji Maeda, Yukari Uemura, Yosuke Shimizu, Kazumi Omata, Masao Matsuoka, Shinya Shimada, Hiroaki Mitsuya · 2022 · Scientific Reports
  69. COVID-19 vaccine effectiveness among people living with and without HIV in South Carolina, USA: protocol of a population-based cohort study
    Xueying Yang, Jiajia Zhang, Bankole Olatosi, Sharon Weissman, Xiaoming Li · 2022 · BMJ Open
  70. Recent advances of nanotechnology in COVID 19: A critical review and future perspective
    Kabi Raj Chaudhary, Sima Kujur, Karanvir Singh · 2022 · OpenNano
  71. Humoral and cellular immunity against diverse SARS-CoV-2 variants
    Changxu Chen, Xin Wang, Zeli Zhang · 2023 · Journal of genetics and genomics/Journal of Genetics and Genomics
  72. Generalidades, aspectos clínicos y de prevención sobre COVID-19: México y Latinoamérica
    José Antonio Morales Fernández, Rosa María Wong‐Chew · 2021 · Universitas Médica
  73. Diverse vaccine platforms safeguarding against SARS-CoV-2 and its variants
    Bhaswati Chatterjee, Suman Siddharth Thakur · 2021 · Expert Review of Vaccines
  74. Model-Based Planning and Delivery of Mass Vaccination Campaigns against Infectious Disease: Application to the COVID-19 Pandemic in the UK
    Dauda Sh. Ibrahim, Zoltán Kis, Kyungjae Tak, Maria M. Papathanasiou, Cleo Kontoravdi, Benoît Chachuat, Nilay Shah · 2021 · Vaccines
  75. Pan-SARS neutralizing responses after third boost vaccination in non-human primate immunogenicity model
    Kirill V. Kalnin, Timothy Plitnik, Michael Kishko, Dean Huang, Alice Raillard, Julie Piolat, Natalie G. Anosova, Timothy J. Tibbitts, Joshua M. DiNapoli, Shrirang Karve et al. · 2022 · Vaccine
  76. HIV and COVID-19 Disease
    Jacqui P. Venturas · 2023 · Seminars in Respiratory and Critical Care Medicine
  77. SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged Mice
    Eun Kim, Muhammad S. Khan, Alessandro Ferrari, Shaohua Huang, Josè Camilla Sammartino, Elena Percivalle, Thomas W. Kenniston, Irene Cassaniti, Fausto Baldanti, Andrea A. Gambotto · 2023 · Microbiology Spectrum
  78. Rapid evolution of the COVID-19 pandemic calls for a unified public health response
    Na He · 2021 · BioScience Trends
  79. Reactogenicity Differences between Adjuvanted, Protein-Based and Messenger Ribonucleic Acid (mRNA)-Based COVID-19 Vaccines
    Matthew D. Rousculp, Kelly A. Hollis, RYAN M. ZIEMIECKI, Dawn M. Odom, Anthony M. Marchese, Mitra Montazeri, Shardul Odak, Laurin Jackson, Hadi Beyhaghi, Seth L Toback · 2024 · Vaccines
  80. Glycoprotein E-Displaying Nanoparticles Induce Robust Neutralizing Antibodies and T-Cell Response against Varicella Zoster Virus
    Hong Wang, Sibo Zhang, Wenhui Xue, Yarong Zeng, Liqin Liu, Lingyan Cui, Hongjing Liu, Yuyun Zhang, Lin Chen, Meifeng Nie et al. · 2024 · International Journal of Molecular Sciences
  81. Effectiveness of interventions to improve vaccine efficacy: a systematic review and meta-analysis
    K S Aviraj, Apoorva Wasnik, Lalima Gupta, Ayushi Ranjan, Harshini Suresh · 2025 · Systematic Reviews
  82. Characteristics of replication and pathogenicity of SARS-CoV-2 Alpha and Delta isolates
    Xiaoli Feng, Dandan Yu, Mi Zhang, Xiaohong Li, Qing‐Cui Zou, Wentai Ma, Jian-Bao Han, Ling Xu, Cuixian Yang, Wang Qu et al. · 2022 · Virologica Sinica
  83. An albumin-angiotensin converting enzyme 2-based SARS-CoV-2 decoy with FcRn-driven half-life extension
    Elisabeth Fuchs, Imke Rudnik‐Jansen, Anders Dinesen, Denis Selnihhin, Ole Aalund Mandrup, Kader Thiam, Jørgen Kjems, Finn Skou Pedersen, Kenneth Alan Howard · 2022 · Acta Biomaterialia
  84. Dynamic SARS-CoV-2 emergence algorithm for rationally-designed logical next-generation vaccines
    David P. Maison, Lauren Lei Ching, Sean B. Cleveland, Alanna C. Tseng, Eileen T. Nakano, Cecilia M. Shikuma, Vivek R. Nerurkar · 2022 · Communications Biology
  85. Mixed formulation of mRNA and protein‐based COVID‐19 vaccines triggered superior neutralizing antibody responses
    Jialu Zhang, Qian He, Xujia Yan, Jianyang Liu, Yu Bai, Chaoqiang An, Bopei Cui, Fan Gao, Qunying Mao, Junzhi Wang et al. · 2022 · MedComm
  86. Immunogenicity and safety of a single booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Primary analysis report of a phase 3 open-label trial
    Kenji Kuriyama, Kyoko Murakami, Taisei Masuda, Kenkichi Sugiura, Sho Sakui, Ron P. Schuring, Mitsuhiro Mori · 2023 · Vaccine
  87. Distinct roles of vaccine-induced SARS-CoV-2-specific neutralizing antibodies and T cells in protection and disease
    Jingyi Yan, Chandrashekar Bangalore Revanna, Negin Nikouyan, Sofia Appelberg, Daniela Nacimento Silva, Haidong Yao, Anna Pasetto, Friedemann Weber, Sofie Weber, Olivia J. Larsson et al. · 2024 · Molecular Therapy
  88. COVID-19 herd immunity v. learning to live with the virus
    S A Madhi · 2021 · South African Medical Journal
  89. Jumping a Moving Train: SARS-CoV-2 Evolution in Real Time
    Ahmed M. Moustafa, Paul Joseph Planet · 2021 · Journal of the Pediatric Infectious Diseases Society
  90. The impact of coronavirus disease 2019 on people with HIV
    Julia del Amo, Asuncion Diaz, Rosa Polo · 2021 · Current Opinion in Infectious Diseases
  91. A Recombinant Subunit Vaccine Induces a Potent, Broadly Neutralizing, and Durable Antibody Response in Macaques against the SARS-CoV-2 P.1 (Gamma) Variant
    Albert To, Teri Ann S. Wong, Michael M. Lieberman, Karen Sue Thompson, Aquena H. Ball, Laurent Pessaint, Jack J. Greenhouse, Nisrine Daham, Anthony Cook, Brandon Narvaez et al. · 2022 · ACS Infectious Diseases
  92. A Modified Fibronectin Type III Domain-Conjugated, Long-Acting Pan-Coronavirus Fusion Inhibitor with Extended Half-Life
    Qianyu Duan, Shuai Xia, Fanke Jiao, Qian Wang, Rui Wang, Lu Lu, Shibo Jiang, Wei Xu · 2022 · Viruses
  93. Genetic Load of SARS-CoV-2 in Aerosols Collected in Operating Theaters
    María Barberá-Riera, Simona Porru, Manuela Barneo‐Muñoz, Andrea Villasante Ferrer, Paula Carrasco, Rosa de Llanos, Antoni Llueca, Juana María Delgado-Saborit · 2022 · Applied and Environmental Microbiology
  94. Post COVID-19 vaccination side effects and associated factors among vaccinated health care providers in Oromia region, Ethiopia in 2021
    Mesfin Tafa Segni, Hailu Fekadu Demissie, Muhammedawel Kaso, Adem Kedir Geleto, Mesfin Wubishet Kelkile, Birhanu Kenate Sori, Melese Lemi Heyi, Dabesa Gobena Iticha, Gemechu Shumi, Abera Botere Guddisa et al. · 2022 · PLoS ONE
  95. Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates
    Patricia Pérez, Guillermo Albericio, David Astorgano, Sara Flores, Cristina Sánchez-Corzo, Pedro J. Sánchez‐Cordón, Joanna Luczkowiak, Rafael Bastos Delgado, José M. Casasnovas, Mariano Estéban et al. · 2023 · Frontiers in Immunology
  96. Prevention and Treatment of SARS-CoV2 Infection in People Living with HIV: The Need for Specific Data
    Natalia Anahí Díaz, Rosa de Miguel Buckley, Fernando Agüero, Omar Gustavo Sued, José Ramón Arribas, Juan Ambrosioni, Juan Ambrosioni, José Luís Blanco, Lorena de la Mora, Felipe García et al. · 2021 · Infectious Diseases and Therapy
  97. SARS-CoV-2 and HIV-1: Should HIV-1-Infected Individuals in Sub-Saharan Africa Be Considered a Priority Group for the COVID-19 Vaccines?
    Wilson Lewis Mandala, Michael K. P. Liu · 2021 · Frontiers in Immunology
  98. Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study
    Javier García‐Pérez, María González-Pérez, María Castillo de la Osa, Alberto Manuel Borobia, Luis Antonio Castaño, M.J. Bertran, Magda Campins, Antonio Portolés, David Lora, Mercedes Bermejo et al. · 2022 · EClinicalMedicine
  99. The resurgence risk of COVID-19 in the presence of immunity waning and ADE effect: a mathematical modelling study
    Weike Zhou, Biao Tang, Yao Bai, Yiming Shao, Yanni Xiao, Sanyi Tang · 2021 · medRxiv
  100. SARS-CoV-2 humoral immunity in people living with HIV-1
    Boitumelo M. Motsoeneng, Jinal N. Bhiman, Simone I. Richardson, Penny L. Moore · 2024 · Trends in Immunology